Angelica Welch


Study Addresses Breast Cancer Monitoring Burden on Metastatic Patients

January 2nd 2019

Melissa K. Accordino, MD, MS, discusses ways to improve the monitoring of patients with metastatic breast cancer.

Expert Reflects on 2018 Lung Cancer Advancements

January 2nd 2019

Joshua K. Sabari, MD, reflects on the rapidly advancing landscape of lung cancer.

Fixed-Duration Venetoclax Triplet Active in CLL

January 1st 2019

Kerry A. Rogers, MD, discusses phase II findings of a trial with obinutuzumab, ibrutinib, and venetoclax and the future of dose-limited regimens in chronic lymphocytic leukemia.

Pembrolizumab Plus BL-8040 Shows Promise in Pancreatic Cancer

December 29th 2018

Manuel Hidalgo, MD, PhD, discusses the potential with BL-8040 and pembrolizumab in pancreatic adenocarcinoma.

Relapsed/Refractory Myeloma Landscape Slated to Expand

December 20th 2018

Samir Parekh, MD, discusses the excitement of selinexor and venetoclax (Venclexta) as possible additions to the myeloma treatment landscape

Pemigatinib Emerging as Potential Second-Line Treatment for Cholangiocarcinoma

December 19th 2018

The potent FGFR1-3 inhibitor pemigatinib showed preliminary efficacy and safety signals in the phase II FIGHT-202 trial (NCT02924376) of patients with previously treated advanced, metastatic or surgically unresectable cholangiocarcinoma.

Cholangiocarcinoma Emerges as Key Target of FGFR Inhibitor Research

December 19th 2018

Sameek Roychowdhury, MD, PhD, discusses the potential for FGFR inhibitors in the treatment of patients with cholangiocarcinoma who harbor FGFR fusions.

Infigratinib Active in Intrahepatic Cholangiocarcinoma

December 19th 2018

The selective pan-FGFR kinase inhibitor infigratinib showed meaningful antitumor activity and a manageable safety profile in patients with previously treated intrahepatic cholangiocarcinoma who harbor FGFR2 fusions.

Expert Reflects on Recent Pivotal Data in RCC

December 18th 2018

Daniel J. George, MD, discusses the status of treatment for patients with high-risk stage III RCC, as well as the role of sunitinib (Sutent) and checkpoint inhibitors in the RCC paradigm.

Eryaspase May Provide Second-Line Option in Pancreatic Cancer

December 18th 2018

Pascal Hammel, MD, PhD, discusses the potential for eryaspase, and the future direction of the pancreatic cancer landscape.

Immunotherapy Could Have Role in Frontline HCC

December 17th 2018

Michael J. Pishvaian, MD, PhD, discusses the impact of immunotherapy in the treatment landscape of hepatocellular carcinoma.

T-DM1 May Provide Less-Toxic Option in Older HER2+ Breast Cancer Population

December 14th 2018

Akihiko Shimomura, MD, PhD, discusses the rationale for the phase III HERB TEA trial of elderly patients with HER2-positive breast cancer.

Following Pivotal Trials, Questions Remain With Bevacizumab in Recurrent Ovarian Cancer

December 14th 2018

Valerie Sugiyama, MD, discusses the treatment of patients with recurrent ovarian cancer.

Powles Navigates Rapidly Evolving Frontline Paradigm in Urothelial Carcinoma

December 13th 2018

Thomas Powles MBBS, MRCP, MD, discusses the changes to the frontline landscape of bladder cancer and where research should focus moving forward.

Real-World Findings Support Nivolumab Use in HNSCC

December 12th 2018

Nivolumab demonstrated durable response and overall survival rates in a real-world analysis of patients with platinum-refractory, recurrent/metastatic head and neck squamous cell carcinoma.

Addressing Off-Target Effects of TKIs in Pediatric CML

December 10th 2018

Briana Patterson, MD, discusses the off-target effects of tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia.

ALK+ NSCLC Paradigm Bursting With Frontline Options

December 1st 2018

Stephen Liu, MD, discusses ongoing developments in the treatment of patients with ALK-positive NSCLC.

Avelumab Continues to Show Value in JAVELIN Merkel 200 Analyses

December 1st 2018

In an analysis of patient-reported outcomes of the JAVELIN Merkel 200 trial of avelumab (Bavencio), investigators found that there was a similarity in proportion of responders with metastatic Merkel cell carcinoma based on clinical and patient-reported outcome endpoints.

Cemiplimab Explored in Advanced Basal Cell Carcinoma

November 30th 2018

An ongoing phase II study evaluating the PD-1 inhibitor cemiplimab in patients with basal cell carcinoma may prove efficacious based on its activity in other advanced malignancies.

Immunotherapy May Have Place Among TKI Boom in EGFR+ NSCLC

November 30th 2018

Within the last decade, 4 tyrosine kinase inhibitors have been approved for the frontline treatment of patients with EGFR-positive non–small cell lung cancer.